Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers

11 Jun, 2021

Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers
Photo by Matthew Fournier on Unsplash

– Kurome Therapeutics announced the closing of a $15m Series A financing.
– The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors.
– The funding will support the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of both targeted therapy and chemotherapy drugs via adaptive resistance mechanisms, having co-opted IRAK1/4-mediated immune signaling pathways to survive.
– The biology being currently investigated was discovered by Daniel Starczynowski, PhD, who is Principal investigator and Co-Leader, Hematologic Malignancies Program at Cincinnati Children’s Cancer and Blood Diseases Institute, and a leading expert in IRAK 1/4 signaling pathways in cancer.

Biotechnology Health Care North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: